Studies have demonstrated that CLL patients harboring TP53 mutations exhibit significantly shorter progression-free and overall survival compared to those without these mutations, even when treated with fludarabine-based regimens [177,178]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.